StageZero Life Sciences Ltd (TO:SZLS) — Market Cap & Net Worth
Market Cap & Net Worth: StageZero Life Sciences Ltd (SZLS)
StageZero Life Sciences Ltd (TO:SZLS) has a market capitalization of $3.58 Million (CA$4.94 Million) as of September 16, 2026. Listed on the TO stock exchange, this Canada-based company holds position #29288 globally and #1362 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying StageZero Life Sciences Ltd's stock price CA$0.04 by its total outstanding shares 123553000 (123.55 Million). Also see total assets of StageZero Life Sciences Ltd for a full breakdown of the balance sheet.
StageZero Life Sciences Ltd Market Cap History: 2015 to 2025
StageZero Life Sciences Ltd's market capitalization history from 2015 to 2025. Data shows change from $21.45 Million to $3.58 Million (-32.83% CAGR). Also see SZLS cash generation efficiency for how efficiently the company converts equity into cash flow.
StageZero Life Sciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how StageZero Life Sciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check StageZero Life Sciences Ltd share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.55x
StageZero Life Sciences Ltd's market cap is 1.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $21.45 Million | $325.81K | -$6.02 Million | 65.84x | N/A |
| 2016 | $221.65 Million | $1.05 Million | -$5.91 Million | 210.27x | N/A |
| 2017 | $164.45 Million | $411.67K | -$2.95 Million | 399.48x | N/A |
| 2018 | $35.75 Million | $185.87K | -$3.94 Million | 192.34x | N/A |
| 2019 | $35.75 Million | $138.70K | -$4.31 Million | 257.75x | N/A |
| 2020 | $67.03 Million | $4.15 Million | -$7.18 Million | 16.15x | N/A |
| 2021 | $26.81 Million | $5.07 Million | -$7.68 Million | 5.29x | N/A |
| 2022 | $5.36 Million | $3.80 Million | -$11.42 Million | 1.41x | N/A |
| 2023 | $4.47 Million | $2.88 Million | -$12.53 Million | 1.55x | N/A |
Competitor Companies of SZLS by Market Capitalization
Companies near StageZero Life Sciences Ltd in the global market cap rankings as of September 16, 2026. Review SZLS goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to StageZero Life Sciences Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #88 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #161 globally with a market cap of $147.88 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #476 globally with a market cap of $56.70 Billion USD ( CN¥387.49 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #578 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #88 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $641.39 |
| #161 | Danaher Corporation | NYSE:DHR | $147.88 Billion | $209.36 |
| #476 | WuXi AppTec Co Ltd | SHG:603259 | $56.70 Billion | CN¥156.67 |
| #578 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $350.78 |
StageZero Life Sciences Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, StageZero Life Sciences Ltd's market cap moved from $21.45 Million to $ 3.58 Million, with a yearly change of -32.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | CA$3.58 Million | 0.00% |
| 2024 | CA$3.58 Million | -20.00% |
| 2023 | CA$4.47 Million | -16.67% |
| 2022 | CA$5.36 Million | -80.00% |
| 2021 | CA$26.81 Million | -60.00% |
| 2020 | CA$67.03 Million | +87.50% |
| 2019 | CA$35.75 Million | 0.00% |
| 2018 | CA$35.75 Million | -78.26% |
| 2017 | CA$164.45 Million | -25.81% |
| 2016 | CA$221.65 Million | +933.33% |
| 2015 | CA$21.45 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 14th, 2026 the market cap of StageZero Life Sciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.58 Million USD |
| MoneyControl | $3.58 Million USD |
| MarketWatch | $3.58 Million USD |
| marketcap.company | $3.58 Million USD |
| Reuters | $3.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more